The fibrinolytic system in man.
The fibrinolytic system comprises a proenzyme, plasminogen, which can be activated to the active enzyme plasmin, that will degrade fibrin by different types of plasminogen activators. Inhibition of fibrinolysis may occur at the level of plasmin or at the level of the activators. Fibrinolysis in human blood seems to be regulated by specific molecular interactions between these components. In plasma, normally no systemic plasminogen activation occurs. When fibrin is formed, small amounts of plasminogen activator and plasminogen adsorb to the fibrin, and plasmin is generated in situ. The formed plasmin, which remains transiently complexed to fibrin, is only slowly inactivated by alpha 2-antiplasmin, while plasmin, which is released from digested fibrin, is rapidly and irreversibly neutralized. The fibrinolytic process, thus, seems to be triggered by and confined to fibrin. Thrombus formation may occur as the result of insufficient activation of the fibrinolytic system and (or) the presence of excess inhibitors, while excessive activation and/or deficiency of inhibitors might cause excessive plasmin formation and a bleeding tendency. Evidence obtained in animal models suggests that tissue-type plasminogen activator, obtained by recombinant DNA technology, may constitute a specific clot-selective thrombolytic agent with higher specific activity and fewer side effects than those currently in use.
Collen
D
D
Lijnen
H R
HR
D000818:Animals; D001528:Behcet Syndrome / Q000097:blood; D001665:Binding Sites; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004617:Embolism / Q000209:etiology; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D007674:Kidney Diseases / Q000097:blood; D007700:Kinetics; D008107:Liver Diseases / Q000097:blood; D008239:Lysine / Q000378:metabolism; D010958:Plasminogen / Q000032:analysis / Q000502:physiology; D010960:Plasminogen Activators / Q000032:analysis / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000502:physiology; D015849:Plasminogen Inactivators; D011247:Pregnancy; D013300:Streptokinase / Q000494:pharmacology; D013927:Thrombosis / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology; D000979:alpha-2-Antiplasmin / Q000032:analysis / Q000172:deficiency / Q000494:pharmacology; D000511:alpha-Macroglobulins / Q000032:analysis
D005343:Fibrinolytic Agents; D015849:Plasminogen Inactivators; D000979:alpha-2-Antiplasmin; D000511:alpha-Macroglobulins; D005337:Fibrin; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin; D014568:Urokinase-Type Plasminogen Activator; D008239:Lysine